The DOI matches its Crossref record; 326 of the 326 references it cites were found in a registry or an index.
The Kallikrein-Kinin System: Current and Future Pharmacological Targets
Open accessAbstract
The kallikrein-kinin system is an endogenous metabolic cascade, triggering of which results in the release of vasoactive kinins (bradykinin-related peptides). This complex system includes the precursors of kinins known as kininogens and mainly tissue and plasma kallikreins. The pharmacologically active kinins, which are often considered as either proinflammatory or cardioprotective, are implicated in many physiological and pathological processes. The interest of the various components of this multi-protein system is explained in part by the multiplicity of its pharmacological activities, mediated not only by kinins and their receptors, but also by their precursors and their activators and the metallopeptidases and the antiproteases that limit their activities. The regulation of this system by serpins and the wide distribution of the different constituents add to the complexity of this system, as well as its multiple relationships with other important metabolic pathways such as the renin-angiotensin, coagulation, or complement pathways. The purpose of this review is to summarize the main properties of this kallikrein-kinin system and to address the multiple pharmacological interventions that modulate the functions of this system, restraining its proinflammatory effects or potentiating its cardiovascular properties.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“During ACE inhibition, bradykinin is primarily inactivated by aminopeptidase P (APP).”
From Sex-dependent and race-dependent association of XPNPEP2 C-2399A polymorphism with angiotensin-converting enzyme inhibitor-associated angioedema (2010) · cites this paper as [8]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2000) · New England Journal of Medicine · doi:10.1056/nejm200001203420301 · Cited by 8,663
Pfeffer, M. A., Braunwald, E., Moyé, L. A., Basta, L., Brown, E. J., Cuddy, T. E., Davis, B. R., Geltman, E. M., Goldman, S., Flaker, G. C., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199209033271001 · Cited by 5,911
Rigat, B., Hubert, C., Alhenc-Gelas, F., Cambien, F., Corvol, P., & Soubrier, F. (1990) · Journal of Clinical Investigation · doi:10.1172/jci114844 · Cited by 3,767
Fredriksson, R., Lagerström, M. C., Lundin, L.-G., & Schiöth, H. B. (2003) · Molecular Pharmacology · doi:10.1124/mol.63.6.1256 · Cited by 2,941
Donoghue, M., Hsieh, F., Baronas, E., Godbout, K., Gosselin, M., Stagliano, N., Donovan, M., Woolf, B., Robison, K., Jeyaseelan, R., et al. (2000) · Circulation Research · doi:10.1161/01.res.87.5.e1 · Cited by 2,485
MEROPS: the peptidase database
Rawlings, N. D., & Barrett, A. J. (1999) · Nucleic Acids Research · doi:10.1093/nar/27.1.325 · Cited by 2,284
Cambien, F., Poirier, O., Lecerf, L., Evans, A., Cambou, J., Arveiler, D., Luc, G., Bard, J., Bara, L., Ricard, S., et al. (1992) · Nature · doi:10.1038/359641a0 · Cited by 1,908
Køber, L., Torp-Pedersen, C. T., Carlsen, J. E., Bagger, H., Eliasen, P., Lyngborg, K., Videbæk, J., Cole, D. S., Auclert, L., Pauly, N., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199512213332503 · Cited by 1,768
Bioregulation of kinins: kallikreins, kininogens, and kininases.
Bhoola, K. D., Figueroa, C. D., & Worthy, K. (1992) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)00058-4 · Cited by 1,744
Angiotensin-converting enzyme 2 is an essential regulator of heart function
Crackower, M. A., Sarao, R., Oudit, G. Y., Yagil, C., Kozieradzki, I., Scanga, S. E., Oliveira-dos-Santos, A. J., da Costa, J., Zhang, L., Pei, Y., et al. (2002) · Nature · doi:10.1038/nature00786 · Cited by 1,733
Research works printed but not linked: 5
- 1 Abelous J, Bardier E. Les substances hypotensives de l’urine humaine normale. CR Soc Biol. 1909;66:511-512. (in French)
- 209 Rosenkrans B, Russmann S, Reichen J, Brunner-Ferber F, Bork K, Knolle J. Clinical proof-of-concept fort he bradykinin B2 antagonist; icatibant in liver cirrhosis and hereditary angioedema. Peptide Receptors Montreal 2004 Symposium. Montreal, Canada, 2004.
- 222 Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:145-153. · DOI · Paper page
- 241 Dumoulin MJ, Lamontagne D, Burnett J, Heublein D, Yamaguchi N, Adam A. Respective role of endogenous kinins and natriuretic peptides in the cardioprotective effect of omapatrilat following total heart ischemia (abstract). Eur Heart J. 2001;22:50.
- 250 Duan Q, Nikpoor B, Molinaro G, Meijer I, Rochefort D, Saint-Onge J, et al. Variants in XPNPEP2 increase susceptibility to ACE-inhibitor associated adverse reactions. Am J Hum Genet. In press 2005.
Cited by
Sorted by citations
Acute Kidney Injury Associated with Cardiac Surgery
Rosner, M. H., & Okusa, M. D. (2005) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.00240605 · Cited by 1,064
A catalog of genetic loci associated with kidney function from analyses of a million individuals
Study, L. C., Wuttke, M., Program, V. A. M. V., Li, Y., Li, M., Sieber, K. B., Feitosa, M. F., Gorski, M., Tin, A., Wang, L., et al. (2019) · Nature Genetics · doi:10.1038/s41588-019-0407-x · Cited by 842
Distribution of 15 Human Kallikreins in Tissues and Biological Fluids
Shaw, J. L. V., & Diamandis, E. P. (2007) · Clinical Chemistry · doi:10.1373/clinchem.2007.088104 · Cited by 390
Bernstein, K. E., Ong, F. S.-C., Blackwell, W.-L. B., Shah, K. H., Giani, J. F., González-Villalobos, R. A., Shen, X. Z., & Fuchs, S. (2013) · Pharmacological Reviews · doi:10.1124/pr.112.006809 · Cited by 330
Pethö, G., & Reeh, P. W. (2012) · Physiological Reviews · doi:10.1152/physrev.00048.2010 · Cited by 299
Metadata
- Authors
- Moreau, M. E., Garbacki, N., Molinaro, G., Brown, N. J., Marceau, F., & Adam, A.
- Affiliations
- Université de Montréal (CA)
- University of Liège (BE)
- Vanderbilt University (US)
- Centre hospitalier universitaire de Québec (CA)
- Venue
- Journal of Pharmacological Sciences
- Publisher
- Japanese Pharmacological Society
- Published
- 2005
- Volume
- 99
- Issue
- 1
- Pages
- 6-38
- ISSN
- 1347-8613 (ISSN-L)
- 1347-8648
- OpenAlex
- W1967632907
- Semantic Scholar
- 11ef9af17a7b09227baf4d743022d17406b6c59a
- Cited by
- 457
- References
- 324
- Citations by year
- 2026: 2 · 2025: 9 · 2024: 19 · 2023: 14 · 2022: 7 · 2021: 20 · 2020: 24 · 2019: 9 · 2018: 20 · 2017: 13 · 2016: 29 · 2015: 23 · 2014: 24 · 2013: 37 · 2012: 33
- FWCI
- 4.07
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Pharmacological Sciences (publishedVersion)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- ORBi (University of Liège) (submittedVersion, other-oa)
- Funders
- National Institutes of Health
- National Heart, Lung, and Blood Institute (R01HL079184)
- Topics
- Health Sciences › Medicine › Hematology › Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pineapple and bromelain studies
- Life Sciences › Immunology and Microbiology › Immunology › Complement system in diseases
- Keywords
- kallikrein-kinin system, bradykinin, kininogen, tissue kallikrein, plasma kallikrein, kinin receptors, metalloproteinases, antiproteases, serpins, pro-inflammatory effects, cardioprotection, renin-angiotensin system, coagulation, complement system, therapeutic target
- MeSH terms
- Angioedema, Angiotensin-Converting Enzyme Inhibitors, Animals, Bradykinin, Cardiovascular Diseases, Complement C1 Inactivator Proteins, Humans, Inflammation, Kallikreins, Aprotinin, Kidney Diseases, Peptidyl-Dipeptidase A, Kinins, Polymorphism, Genetic, Pyridines, Thiazepines, Neprilysin, Serpins, Randomized Controlled Trials as Topic, Kallikrein-Kinin System, Receptor, Bradykinin B2, Receptor, Bradykinin B1, Complement C1 Inhibitor Protein, Bradykinin B2 Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
